FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D C | 20540 |
|--------------|------|-------|
| wasiiiigton, | D.C. | 20049 |

| STATEMENT | OF | CHANGES | IN B | ENEFIC | IAL (| OWNER | RSHIP |
|-----------|----|----------------|------|---------------|-------|-------|-------|
| | | | | | | | |

| OMB APPROVAL | | | | | | | |
|-----------------------|-------|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | |
| Estimated average b | urden | | | | | | |
| houre per reenonee | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Ford Robert B | | | | | 2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT] | | | | | | | (Ched | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | |
|--|--|--|--|--|---|---|---------|-------------------|--|-------------------|---|------------------|--|---|--|--|--|--|-------------------------|
| (Last) 100 ABE | (F BOTT PAR | First) K ROAD | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 02/21/2024 | | | | | | | X | below) | give title | N AN | Other (s below) | pecify | |
| (Street) ABBOT | ΓPARK II | State) | 60064 (Zip) | | _ 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | Line) | Individual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (| naie) | (Σιμ) | | R | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | action 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 3, 4) 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) | | | and 5) Securities Beneficially Owned Following | | Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | | | | |
| | | | | | | | | Code | v | Amount (A) or (D) | | Price | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | | |
| Common shares without par value 02/21 | | | | | 21/20 | /2024 A 70,332 ⁽¹⁾ A | | \$ <mark>0</mark> | 251,669 | | | D | | | | | | | |
| Common shares without par value | | | | | | | | | | | | | | | 197,4 | 103(2) | | I | Ford Family Trust |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| Derivative Conversion Date | | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Yea | | Code (Instr. | | | | 6. Date Exercisab Expiration Date (Month/Day/Year) | | of Securities | | urity | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficia Owned Following Reported Transacti | re Over Ses For Direct Over Ses Over Se | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | | Date Exercisabl | | xpiration ate | Title | or Nu | nount mber Shares | nt er | Transaction(s) (Instr. 4) | | | |
| Option (right to buy) ⁽³⁾ | \$116.98 | 02/21/2024 | | | A | | 264,293 | | 02/21/202 | 5 02 | 2/20/2034 | Commor Shares | 26 | 4,293 | \$0 | 264,29 | 93 | D | |

Explanation of Responses:

- 1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- $2. \ Held \ in the Ford \ Family \ Trust \ DTD \ June \ 2, 2014. \ The \ reporting \ person \ is \ co-trustee \ of \ the \ trust.$
- 3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 88,097 on February 21, 2025, 88,098 on February 21, 2026, and 88,098 on February 21, 2027.

/s/ Robert B. Ford by Jessica H.

Paik, Attorney-in-Fact ** Signature of Reporting Person

02/23/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.